Returns | 1W : -3.1% , 1M : -2.3%,1Y : 145.3% |
LT :   |
    Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : Average [>25% and <50%] |
Peers & Returns | 1W | 1M | 1Y |
MANGALAM DRUGS & ORGANICS | -3.1% | -2.3% | 145.3% |
SUN PHARMACEUTICAL INDUSTRIES | 3.4% | 6.4% | 39.2% |
DR REDDYS LABORATORIES | -0.4% | 11.7% | 26.7% |
DIVIS LABORATORIES | 0.6% | 12.6% | 59.7% |
CIPLA | 4.8% | 19.4% | 56.3% |
BIOCON | 0.6% | 3.5% | 18% |
AUROBINDO PHARMA | 5.4% | 14.8% | 74.8% |
LUPIN | 1.5% | 0.6% | 27.8% |
TORRENT PHARMACEUTICALS | 1.6% | 5% | 12.5% |
Ratio | Value |
---|---|
P/E P/B P/S |
20.47
P/E Calculated based on EPS of 5.21
[ Mar2020 - Standalone Results ] 1.62
P/B Calculated based on Book Value of 65.67
[ Mar2020 - Standalone Results ] 0.53
P/S Calculated based on Revenues of 320.953 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
29% -22% -23% |
Pledged Shares |
33.57 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |